The Experimental Drug Against Lung Cancer Prolongs Patients’ Lives. Part 2 of 3

The Experimental Drug Against Lung Cancer Prolongs Patients’ Lives – Part 2 of 3

About half of patients experienced nausea, vomiting and diarrhea but these side effects eased over time. The fusion gene was first discovered to play a situation in this type of lung cancer in 2007. Researchers are now working on a phase 3 trial of the drug. The Korean researchers reported financial ties to Pfizer.

chemotherapy

The second study, a state 3 trial, involved 451 patients with advanced non-small cell lung cancer aged 70 to 89. The study had first expected to enroll 520 patients, but it was halted first when good survival results were seen in the group taking the combination therapy.

Currently, elderly patients are typically given just one chemotherapy drug, with younger patients more likely to get two or more. In this trial, participants were randomly selected to take either one chemotherapy agent – gemcitabine (Gemzar) or vinorelbine (Navelbine) – or to receive both carboplatin and paclitaxel (Taxol).

Parts: 1 2 3

Advertisements

2 thoughts on “The Experimental Drug Against Lung Cancer Prolongs Patients’ Lives. Part 2 of 3

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s